Early Activity of Neoadjuvant Niraparib in HRD+ Ovarian Cancer Reported in NANT Trial
March 19th 2022Patients with BRCA-mutant, homologous repair deficiency–positive advanced resectable ovarian cancer may benefit from treatment with neoadjuvant niraparib, according to early results of a phase 2 trial reported at 2022 SGO.
Long-Term PFS Benefit With Olaparib in nonBRCA-Mutant Ovarian Cancer More Likely With HRD Positivity
March 18th 2022Long-term progression-free survival was associated with various clinical and molecular factors in patients receiving olaparib who had platinum-sensitive relapsed ovarian cancer and no germline mutations in BRCA1/2.
Ronnie Shapira-Frommer, MD, Discusses Multidisciplinary Care to Treat Gynecologic Malignancies
April 12th 2021CancerNetwork® spoke with Ronnie Shapira-Frommer, MD, during the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer about her thoughts on the effect of the conference content across multidisciplinary specialties.